1. Show article details.

    Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GlobeNewswire – 4:30 PM ET 07/02/2020

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced grants of stock options to ten new employees to purchase an aggregate of 112,600 shares of the Company’s common stock with an exercise price of $23.30 per share, the closing price of Assembly’s common stock...

  2. Show article details.

    Assembly Biosciences Initiates Phase 2 Trial Evaluating Second-Generation Core Inhibitor ABI-H2158 for Chronic Hepatitis B Infection

    GlobeNewswire – 8:00 AM ET 06/25/2020

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced the initiation of a Phase 2 trial of its potent, second-generation core inhibitor, ABI-H2158.

  3. Show article details.

    Preclinical Data from Assembly Biosciences’ Immuno-Oncology Microbiome Program Featured at AACR’s Virtual Annual Meeting II

    GlobeNewswire – 8:45 AM ET 06/22/2020

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced that preclinical data from its immuno-oncology microbiome program are currently being featured in an e-poster at the American Association for Cancer Research Virtual Annual Meeting II, June 22-24, 2020.

  4. Show article details.

    BRIEF-Assembly Biosciences -Termination Of Collaboration Agreement With Abbvie Will Be Effective 120 Days Following Notice Of Termination On October 10

    Reuters – 4:21 PM ET 06/18/2020

    Abbvie Inc (ABBV): * ASSEMBLY BIOSCIENCES (ASMB) - TERMINATION OF COLLABORATION AGREEMENT WITH ABBVIE WILL BE EFFECTIVE 120 DAYS FOLLOWING NOTICE OF TERMINATION ON OCTOBER 10. * ASSEMBLY BIO - WILL REGAIN WORLDWIDE RIGHTS TO ALL MICROBIOME GASTROINTESTINAL PROGRAMS LICENSED UNDER COLLABORATION AGREEMENT WITH ABBVIE Source text: https://bit.ly/3ecUTYk Further company coverage:

  5. Show article details.

    BRIEF-Assembly Biosciences Regains Worldwide Rights To Microbiome Gastrointestinal Development Programs

    Reuters – 4:13 PM ET 06/18/2020

    Assembly Biosciences Inc (ASMB): * ASSEMBLY BIOSCIENCES REGAINS WORLDWIDE RIGHTS TO MICROBIOME GASTROINTESTINAL DEVELOPMENT PROGRAMS. * Assembly Biosciences Inc (ASMB) - PROCESS TO EXPLORE STRATEGIC ALTERNATIVES UNDERWAY. * ASSEMBLY BIOSCIENCES (ASMB) - WILL REGAIN WORLDWIDE RIGHTS TO ALL MICROBIOME GASTROINTESTINAL PROGRAMS LICENSED UNDER COLLABORATION AGREEMENT WITH ABBVIE.

  6. Show article details.

    Assembly Biosciences Regains Worldwide Rights to Microbiome Gastrointestinal Development Programs

    GlobeNewswire – 4:01 PM ET 06/18/2020

    -- Process to explore strategic alternatives underway -- Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced that the Company will regain worldwide rights to all microbiome gastrointestinal programs licensed under its collaboration agreement with AbbVie.

  7. Show article details.

    Assembly Biosciences Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    GlobeNewswire – 4:18 PM ET 06/01/2020

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced grants of inducement awards to both its Chief Scientific Officer, Virology, William Delaney, Ph.D., and eight new employees on May 27, 2020 and June 1, 2020, respectively.

  8. Show article details.

    Assembly Biosciences Announces Management Transition

    GlobeNewswire – 8:00 AM ET 05/27/2020

     -- Expert Virologist and Biologist William Delaney, PhD joins as Chief Scientific Officer, Virology --  -- EVP and CSO of Virology Operations Richard Colonno, PhD to retire -- Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced the appointment of William De...

  9. Show article details.

    Assembly Biosciences to Present During the Jefferies Virtual Healthcare Conference

    GlobeNewswire – 8:00 AM ET 05/26/2020

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced that John McHutchison, AO, MD, Chief Executive Officer and President, will present during the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 1:30 pm ET.

  10. Show article details.

    Assembly Biosciences Announces Move to Virtual-Only Annual Meeting of Stockholders on June 11, 2020

    GlobeNewswire – 4:05 PM ET 05/19/2020

    Assembly Biosciences, Inc. (ASMB) today announced that it will hold its 2020 Annual Meeting of Stockholders solely by means of remote communication. Stockholders will not be able to attend the Annual Meeting in person at a physical location.

  11. Show article details.

    Assembly Biosciences Reports Updates on Corporate Progress and First Quarter 2020 Financial Results

    GlobeNewswire – 4:05 PM ET 05/07/2020

    -- Advancing the development of three clinical-stage core inhibitor candidates in HBV portfolio ---- Cash position of $249 million projected to fund operations into 2022 ---- Company to host HBV portfolio progress update call / webcast today at 1:30 pm PT / 4:30 pm ET -- SOUTH SAN FRANCISCO, Calif., May 07, 2020 -- Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing in...

  12. Show article details.

    Preclinical Data from Assembly Biosciences’ Microbiome Program in Ulcerative Colitis Featured in DDW 2020 Virtual Meeting Portal and Upcoming Journal Supplements

    GlobeNewswire – 8:00 AM ET 05/04/2020

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced that the abstract accepted as an ePoster presentation at Digestive Disease Week 2020 Virtual Meeting may now be viewed at the online meeting portal.

  13. Show article details.

    Assembly Biosciences Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

    GlobeNewswire – 5:00 PM ET 05/01/2020

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced grants of stock options to two new employees to purchase an aggregate of 7,000 shares of Assembly’s common stock with an exercise price of $17.01 per share, the closing price on May 1, 2020.

  14. Show article details.

    Assembly Biosciences to Host Conference Call and Webcast to Review HBV Portfolio Progress

    GlobeNewswire – 4:05 PM ET 04/30/2020

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced plans to host a conference call and live audio webcast on Thursday, May 7, 2020 at 1:30 pm PT / 4:30 pm ET.

  15. Show article details.

    Research by Assembly Biosciences and Academic Collaborators Published in Hepatology Indicates cccDNA Turnover Time May Enable Hepatitis B Cures Following Finite Therapy

    GlobeNewswire – 8:00 AM ET 04/06/2020

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced that results from a research study evaluating the turnover rate of covalently closed circular DNA, which plays a pivotal role in the establishment and persistence of HBV infection, has been published in Hep...

  16. Show article details.

    Assembly Biosciences Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

    GlobeNewswire – 4:05 PM ET 03/31/2020

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced a grant of inducement awards to its Chief Legal and Business Officer, Jason A. Okazaki on March 26, 2020.

  17. Show article details.

    Assembly Biosciences Appoints Jason Okazaki as Chief Legal and Business Officer

    GlobeNewswire – 8:00 AM ET 03/30/2020

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced the appointment of Jason Okazaki as Chief Legal and Business Officer.

  18. Show article details.

    Assembly Biosciences Reports Fourth Quarter and Year End 2019 Financial Results

    GlobeNewswire – 4:05 PM ET 03/04/2020

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today reported financial results and recent highlights for the fourth quarter and year ended December 31, 2019.

  19. Show article details.

    Assembly Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference

    GlobeNewswire – 8:00 AM ET 02/19/2020

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced that John McHutchison, AO, MD, Chief Executive Officer and President will present at the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020 at 2pm ET.

Page:

Today's and Upcoming Events

  • Aug
    10

    ASMB to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    07

    ASMB announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.